

FDA Drug Safety Communication: FDA warns about prescribing and dispensing errors resulting from brand name confusion with antidepressant Brintellix (vortioxetine) and antiplatelet Brilinta (ticagrelor).

August 12, 2015

MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; July 30, 2015.

<https://psnet.ahrq.gov/issue/fda-drug-safety-communication-fda-warns-about-prescribing-and-dispensing-errors-resulting>

[Look-alike and sound-alike](#) drug names can [contribute](#) to confusion and result in medication errors. To raise awareness of potential wrong-patient errors due to similarity between two proprietary names, this announcement describes near misses with the drugs at the prescribing and [dispensing](#) stage and suggests clinicians use the generic names for the medications to reduce risk of patient harm.